Device Trial Radar · NCT07645183
Advanced Technology for Myopia Control in Children and Young Adults
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Jul 1, 2025
Primary completion
May 30, 2026
Study completion Jun 6, 2026
Sponsor
- Lead sponsor
- University of FaisalabadAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 8 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Myopia, or nearsightedness, is increasing rapidly worldwide, especially in children and young adults. This study tested two advanced treatments for slowing myopia progression with one control group: special lenslet spectacles (Stellest with highly aspherical lenslet technology) and violet excitation filter glasses (wavelength 420 nm) and Single vision lenses for controls. The study enrolled 90 participants aged 8 to 20 years from schools and universities in Faisalabad, Pakistan. Participants were randomly assigned to one of three groups: lenslet spectacles, violet filter glasses, or single vision lenses (control group). Visual acuity, contrast sensitivity, Spherical Equivalent and axial length were measured at the start and again after 3, 6, and 9 months and one follow up after cessation of treatment. The study aimed to determine whether these advanced technologies can effectively slow myopia progression compared to standard glasses, providing head-to-head evidence on emerging and established optical interventions for myopia control.
Conditions
- Myopia (Disorder)
- Refraction Error
Interventions
Lenslet SpectaclesDevice
The lenslet spectacles are specially designed spectacle lenses featuring HALT (Highly Aspheric Lenslet Target) technology manufactured by Essilor International (Serial Number: 72426930). The lens design includes a clear distance zone in the center with peripheral areas providing single vision correction. Technical specifications: 5H green covering, multi-dimensional pattern, 1.6mm thickness, refractive index 1.56, UV 400nm protection, antireflective coating. Participants are instructed to wear the spectacles throughout all waking hours. Each participant receives a new pair at baseline. No adjustments are made during the 12-month treatment period unless vision changes require prescription update.
Violet Excitation Filter GlassesDevice
The violet excitation filter glasses are prescription glasses incorporating a violet light filter with wavelength 420 nm (range 360-420 nm). Material: CR-39. Filter intensity: 700 nm. Wavelength verified using spectrophotometer (standard error ±0.1 to 1 nm). Participants are instructed to wear the glasses for 3 hours daily, specifically from 11 AM to 2 PM, to optimize impact on circadian rhythm while avoiding disruption of sleep patterns. Each participant receives a new pair at baseline. The filter is integrated into the prescription lenses.
Single Vision LensesDevice
Standard single vision spectacle lenses (SVS index 1.56) with no myopia control features. These are conventional prescription glasses that correct refractive error but do not incorporate lenslet technology or violet filtering. Participants are instructed to wear the glasses throughout all waking hours. Each participant receives a new pair at baseline.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Axial LengthTime frame: Baseline, Month 3, Month 6, Month 9
- Change in Cycloplegic RefractionTime frame: Baseline, Month 3, Month 6, Month 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The University of Faisalabad
Faisalābad, Punjab Province, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.